...
首页> 外文期刊>Current opinion in microbiology >Superbugs in the coming new decade; multidrug resistance and prospects for treatment of Staphylococcus aureus, Enterococcus spp. and Pseudomonas aeruginosa in 2010
【24h】

Superbugs in the coming new decade; multidrug resistance and prospects for treatment of Staphylococcus aureus, Enterococcus spp. and Pseudomonas aeruginosa in 2010

机译:未来十年的超级错误;多药耐药性和金黄色葡萄球菌肠球菌的治疗前景。和2010年的铜绿假单胞菌

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

New resistance problems have emerged recently among hospital and community-acquired pathogens such as in Staphylococcus aureus, Enterococcus faecium and Pseudomonas aeruginosa. Hospital-acquired and now community-acquired methicillin-resistant S. aureus are emerging worldwide whereas vancomycin-resistant S. aureus remain extremely rare. Hospital-acquired outbreaks of vancomycin-resistant enterococci and multidrug resistant Pseudomonas aeruginosa infections are increasingly reported worldwide. Whereas novel molecules are being developed for treating Gram-positive infections, difficult to non possible-to-treat pandrug-resistant P. aeruginosa infections may become a therapeutic challenge soon.
机译:最近在医院和社区获得的病原体中出现了新的耐药性问题,例如在金黄色葡萄球菌,粪肠球菌和铜绿假单胞菌中。医院获得的和现在社区获得的耐甲氧西林金黄色葡萄球菌正在世界范围内出现,而耐万古霉素的金黄色葡萄球菌仍然极为罕见。在世界范围内,越来越多的医院获得了耐万古霉素的肠球菌和多药耐药的铜绿假单胞菌感染的暴发。尽管正在开发用于治疗革兰氏阳性感染的新型分子,但难以治疗的耐药性铜绿假单胞菌感染可能很快将成为治疗挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号